

1 **Molecular epidemiology of HIV-1 infection in Europe: an overview**

2

3 Apostolos Beloukas^{1,2,*}, Alexandros Psarris^{1*}, Polina Giannelou¹, Evangelia Kostaki¹,
4 Angelos Hatzakis¹, Dimitrios Paraskevis¹

5 ¹Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and
6 Kapodistrian University of Athens, Athens, Greece,

7 ²Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom.

8

9 * A. Beloukas and A. Psarris contributed equally to this work and they will jointly share the
10 first authorship.

11 **Words: 5, 699 / Abstract: 297 / Figures: 3 / References: 127**

12 **Correspondence to:** Dimitrios Paraskevis, Assistant Professor of Epidemiology and
13 Preventive Medicine at the Department of Hygiene, Epidemiology and Medical Statistics of
14 the University of Athens Medical School; 75 Mikras Asias str. PC: 11527, Athens, Greece

15 E-mail: dparask@med.uoa.gr

16 **Abbreviations¹**

¹ *AIDS, Acquired immunodeficiency syndrome; CRF, Circulating recombinant form; DRC, Democratic Republic of Congo; EU, European Union; EEA, European Economic Area, ECDC, European Centre for Disease Prevention and Control; ESAR, European Society for Translational Antiviral Research; HIV, Human immunodeficiency virus; MSM, Men who have sex with men; MSW, Men having sex with women; PR, Protease; PWID, People Who Inject Drugs; RT, Reverse transcriptase; SIV, Simian Immunodeficiency Viruses; SPREAD, Strategy to Control Spread of HIV Drug Resistance; tMRCA, time to Most Recent Common Ancestor, URF, Unique recombinant form; WHO, World Health Organization*

Highlights

- Non-B subtypes increased their prevalence across Western and Central Europe
- In Eastern European countries, except Russia, **subtypes' distribution remains** stable
- Most prevalent non-B subtypes are A, C, F and G and the recombinants CRF01, CRF02
- **Migration from high prevalent areas** is the reason for introducing divergent strains
- **Non-prevalent clades are more frequent circulate amongst immigrant populations**

17 **Abstract (297 words)**

18 **Human Immunodeficiency Virus type 1 (HIV-1) is characterised by vast genetic diversity.**
19 **Globally circulating HIV-1 viruses are classified into distinct phylogenetic strains**
20 **(subtypes, sub-subtypes) and several recombinant forms. Here we describe the**
21 **characteristics and evolution of European HIV-1 epidemic over time through a review of**
22 **published literature and updated queries of existing HIV-1 sequence databases. HIV-1**
23 **in Western and Central Europe was introduced in the early-1980s in the form of subtype**
24 **B, which is still the predominant clade. However, in Eastern Europe (Former Soviet Union**
25 **(FSU) countries and Russia) the predominant strain, introduced into Ukraine in the mid-**
26 **1990s, is subtype A (A_{FSU}) with transmission mostly occurring in people who inject drugs**
27 **(PWID). In recent years, the epidemic is evolving towards a complex tapestry with an**
28 **increase in the prevalence of non-B subtypes and recombinants in Western and Central**
29 **Europe. Non-B epidemics are mainly associated with immigrants, heterosexuals and**
30 **females but more recently, non-B clades have also spread amongst groups where non-B**
31 **strains were previously absent - non-immigrant European populations and amongst men**
32 **having sex with men (MSM). In some countries, non-B clades have spread amongst the**
33 **native population, for example subtype G in Portugal and subtype A in Greece, Albania**
34 **and Cyprus. Romania provides a unique case where sub-subtype F1 has predominated**
35 **throughout the epidemic. In contrast, HIV-1 epidemic in FSU countries remains more**
36 **homogeneous with A_{FSU} clade predominating in all countries. The differences between the**
37 **evolution of the Western epidemic and the Eastern epidemic may be attributable to**
38 **differences in transmission risk behaviours, lifestyle and the patterns of human mobility.**
39 **The study of HIV-1 epidemic diversity provides a useful tool by which we can**
40 **understand the history of the pandemic in addition to allowing us to monitor the spread**
41 **and growth of the epidemic over time.**

42 **Key Words:** HIV-1; subtypes; molecular epidemiology; European HIV-1 epidemic;
43 phylogeny; genetic diversity

44 1. Introduction

45

46 The Human immunodeficiency virus type 1 (HIV-1) epidemic is the most devastating in
47 human history and remains a global public health problem with an estimated 2.5 million
48 people living with HIV in the WHO European area in 2014 ((ECDC), 2015; Tebit and Arts,
49 2011; UNAIDS, 2013). Around half of these people are undiagnosed making identification of
50 transmission networks important for targeted public health intervention programmes.

51 The origins of HIV can be traced to multiple zoonotic infections with Simian
52 Immunodeficiency Viruses (SIV) from African non-human primates with the first HIV
53 transmissions identified as occurring in the Democratic Republic of Congo (DRC) in the early
54 1920s (Faria et al., 2014). There two major types of HIV, HIV type 1 and HIV type 2 (HIV-
55 2), with HIV-2 differing genetically by more than 55% from HIV-1 and being far less
56 widespread. HIV-1 is characterised by its high genetic variability caused by its high
57 replication rate, recombination and error-prone replication due to lack of proof reading
58 activity of the reverse transcriptase enzyme resulting in high substitution rate. (Peeters and
59 Sharp, 2000; Seillier-Moiseiwitsch et al., 1994). It is classified into four distinct groups: M
60 (major), O (outlier), N (non-M, non-O), and P that was more recently identified, **each**
61 **corresponding to independent cross-species transmissions of SIVs from chimpanzees of**
62 **the Central subspecies (*Pan troglodytes troglodytes*) and in Western lowland gorillas**
63 **(*Gorilla gorilla gorilla*)** (D'Arc et al., 2015; Gao et al., 1999; Peeters et al., 1989; Plantier et
64 al., 2009; Simon et al., 1998; Van Heuverswyn et al., 2006) (**Figure 1**). Groups N and P
65 viruses are geographically restricted to Central-Western Africa, notably Cameroon (Ayoub et
66 al., 2000; Peeters et al., 1997; Vallari et al., 2011).

67 Group M viruses are responsible for the HIV-1 global pandemic, spreading out from Central
68 Africa and are further classified in multiple phylogenetically distinct subtypes (A-D, F-H, J
69 and K), sub-subtypes (A1, A2, F1 and F2) and recombinant forms. Existing clades (subtypes,
70 sub-subtypes and recombinants) can further recombine resulting in new mosaic forms (**Figure**
71 **2**). Recombinants **include an expanding list of 79 circulating recombinant forms (CRFs)**
72 and multiple unique recombinant forms (URFs)
73 (www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html).

74 The HIV-1 subtypes/sub-subtypes global distribution is highly heterogeneous and varies
75 geographically (Hemelaar, 2012). In 2004, subtype C was the most prevalent subtype
76 globally, accounting for up to 50% of all infections, followed by A and B, with 12% and 10%
77 respectively. However, subtype A viruses predominate in Central and Eastern African
78 countries (Kenya, Uganda, Tanzania, and Rwanda), as well as in Eastern European countries
79 formerly constituting the Soviet Union (FSU countries). **Subtype B is the main HIV-1 clade**
80 **in Western and Central Europe², North America (including USA, Canada, Mexico), as**
81 **well as in several countries in Central and South America, Caribbean, Australia,**
82 **Northern Africa, and in the Middle East** (Buonaguro et al., 2007).

83 **Based on the earliest AIDS diagnoses and molecular phylogenetic analyses of early**
84 **strains, the introduction of HIV-1 in Europe dates back the to early-1980s** (Brunet et al.,
85 1984; Glauser and Francioli, 1984; Melbye et al., 1984; Robbins et al., 2003). At that time,
86 most infections were due to subtype B viruses and mainly associated with sexual
87 transmissions among men having sex with other men (MSM) or men having sex with women
88 (MSW), transfusions (**haemophiliacs**), and People Who Inject Drugs (PWID) (Brunet et al.,
89 1984; Melbye et al., 1984). **Over the last 15 years, the molecular epidemiology of different**
90 **HIV-1 subtypes and CRFs, referred to hereafter as HIV-1 clades, in Europe has**

² *Classification of European countries into regions was according to the ECDC/WHO criteria*

91 **significantly changed becoming more heterogeneous** (Abecasis et al., 2013; Hemelaar,
92 2011). **The increasing complexity raises plausible questions about potential issues in**
93 **diagnosis, clinical management and even in pathogenesis** (Camacho, 2006; Chaix et al.,
94 2013; Easterbrook et al., 2010; Geretti et al., 2009; Hemelaar, 2013; Paraskevis et al., 2013b;
95 Santoro and Perno, 2013; Scherrer et al., 2011; Siemieniuk et al., 2013; Touloumi et al.,
96 2013). **Investigation of the European HIV-1 epidemic by means of molecular**
97 **epidemiology provides valuable information to investigate and monitor the epidemic's**
98 **dynamics over time** (Frost and Pillay, 2015; Kuhnert et al., 2014; Pybus and Rambaut, 2009;
99 Stadler and Bonhoeffer, 2013; Stadler et al., 2012). **Interestingly, knowledge of the global**
100 **HIV-1 clades' distribution along with population distribution within a given area can,**
101 **by itself, provide insights into transmission dynamics.**

102 **2. HIV-1 epidemiology in Europe**

103

104 **The cumulative number of diagnosed HIV-1 infections in the European continent (i.e**
105 **European Union, European Economic Area (EU/EEA), Russia and FSU countries)**
106 **reached 1,840,136 by the end of 2014 with 49% of these diagnosed in Russia, as reported**
107 **by The European Surveillance System (TESSy), a joint ECDC/WHO database for**
108 **HIV/AIDS surveillance ((ECDC), 2015). In 2014, there were 142,197 newly diagnosed**
109 **HIV-1 infected individuals in EU/EEA and Russia comprising the highest number since**
110 **reporting started in the 1980s ((ECDC), 2015; AIDS, 2015). Of these new infections, 77%**
111 **were diagnosed in the East, 19.2% in the West and 3.5% in the Centre of the European**
112 **continent (using the TESSy/WHO criteria for the geographical division). The incidence**
113 **was found to be more than 7 times higher in the Eastern than in the Western European**
114 **countries (43.2 vs 6.4 per 100, 000 people) and considerably lower in the Central ones (2.6**
115 **per 100, 000) ((ECDC), 2015). Despite public health intervention strategies and extensive**
116 **prevention programmes to eliminate new HIV-1 infections implemented in the last 10 years in**
117 **Europe, the rate of new infection has remained rather stable from 6.7 in 2005 to 6.4 per**
118 **100,000 in 2014 (both adjusted for reporting delay). Interestingly, about one third of newly**
119 **acquired HIV-1 infections are among immigrants (including foreign born individuals), whilst**
120 **two thirds are among natives. The predominant route of HIV-1 transmission is sex between**
121 **men, with a considerable increase in the rate of new HIV-1 infections among MSM from 30%**
122 **in 2005 to 42% in 2014 ((ECDC), 2015). In Eastern European countries HIV-1 transmission**
123 **through heterosexual intercourse is considered the main reason for the increased rate of new**
124 **infections, while transmission through PWID networks also remains high.**

125 3. Overview of HIV-1 diversity in Europe

126

127 The geographical distribution and prevalence of HIV-1 clades in the European continent are
128 highly heterogeneous. Briefly, since their introduction subtype B clade has predominated in
129 most Western and Central European countries (**Western-type epidemic**), whilst in Eastern
130 Europe the epidemic has been dominated by subtype A (A_{FSU}) (**Eastern-type epidemic**)
131 (Abecasis et al., 2013; Hemelaar, 2011). Interestingly though, the molecular epidemiology of
132 the epidemic in West and Central Europe has significantly changed over the last 15 years.
133 **Non-B and/or CRF clades have been introduced mainly through waves of migration**
134 **from areas where are predominant and have been spread through population mobility**
135 **between European countries. Subsequently their prevalence in the Central and Western**
136 **European region have been increased, because of dispersal through European and**
137 **mainly regionally restricted MSM, PWID and heterosexual transmission networks**
138 **increasing the complexity of the epidemic** (Abecasis et al., 2013; de Oliveira et al., 2010;
139 Fabeni et al., 2015; Fox et al., 2010; Hemelaar, 2011; Hoenigl et al., 2016; Simonetti et al.,
140 2014; Tamalet et al., 2015). Subtype B clade still predominates in Western and Central
141 European countries, but each country has a unique pattern shaped by different regional
142 circumstances and high prevalent local transmission routes.

143 Conversely, in Eastern Europe the A_{FSU} clade has predominated since the mid-1990s, when
144 Russia and other FSUs had a very low incidence of HIV-1. Transmissions usually occurred
145 through sexual intercourse and there were a large number of circulating strains, including B
146 clade (Bobkova, 2013). At this stage the absolute number of cases was small and cases were
147 largely confined to MSM. An explosive spread of an HIV-1 subtype A with very low genetic
148 diversity was noted first in Ukraine in 1994 (Novitsky et al., 1998) and thereafter in Russia
149 and Belarus (Bobkova, 2013), Azerbaijan (Saad et al., 2006a), Georgia (Zarandia et al., 2006)

150 and Armenia (Laga et al., 2015) amongst PWID. This subtype has been variably termed
151 subtype IDU-A or A_{FSU} (subtype A associated with states from the former Soviet Union) and
152 is largely confined to PWID (Bobkov et al., 1997; Bobkov et al., 2004; Bobkova, 2013).
153 Phylogenetic investigation of HIV-1 strains from Kiev, Crimea, Donetsk, Poltava and Odessa
154 revealed that subtypes A and B were simultaneous introduced into Ukraine (Bobkova, 2013),
155 however A_{FSU} strains spread successfully across the FSU territory evolving into one of the
156 fastest growing epidemics in the world, (Bobkova, 2013). HIV-1 subtype B clade infections
157 remained stable in the area circulating mostly among MSMs (Thomson et al., 2009).

158

159 4. Prevalence of HIV-1 subtypes in Europe

160

161 To describe the evolution of the European epidemic over time, including the changes in the
162 prevalence of different clades, we used data from the SPREAD cohort (Strategy to Control
163 Spread of HIV Drug Resistance); part of the ESAR collaboration (European Society for
164 Translational Antiviral Research) (Abecasis et al., 2013), **and the published review on the**
165 **global prevalence of different HIV-1 subtypes by Hemelaar *et al.*** (Hemelaar, 2011). The
166 SPREAD/ESAR cohort enrolls newly diagnosed patients from 20 European countries and
167 Israel, while the Hemelaar *et al* review reported estimates in Europe between 2004-2007
168 (Hemelaar, 2011). The SPREAD cohort database reveals B clade as predominant (70.2%) in
169 newly HIV-1 diagnosed patients, after adjusting for oversampling in some countries, followed
170 by C, CRF02_AG, G and A, with 5.0%, 4.9%, 4.8% and 3.6%, respectively. However, there
171 are countries, such as Portugal, Cyprus, Sweden and Greece, where subtype B viruses are less
172 prevalent in new infections (<50%), whilst in the Czech Republic, Germany, Spain, Slovenia
173 and Poland the prevalence of B clade exceeds 80%. Non-B and CRF clades have mainly been
174 associated with immigrants, heterosexual transmission and male gender. Conversely, there is
175 evidence for regional dispersal among native population of subtype A in Greece and subtype
176 G in Portugal (Carvalho et al., 2015; Esteves et al., 2003; Paraskevis et al., 2007). Notably
177 and unlike any other European country, in Romania the F clade (sub-subtype F1) has
178 predominated since the beginning of the epidemic in the late-1980s with as little as 5% of
179 characterised HIV-1 strains belonging to non-F1 subtypes (Apetrei et al., 1998; Stanojevic et
180 al., 2012). However, by 2007 the prevalence of non-F1 strains in treatment naïve individuals
181 showed an increase up to 23% and included clades C, B and A (Paraschiv et al., 2007).

182 Aligned with the SPREAD cohort data, Hemelaar *et al*, reported the B clade accounted for
183 85.2% of the total infections in Western and Central European countries between 2004-2007.

184 Among the non-B clades, CRF02_AG was the most prevalent (4.5%) followed by C and A
185 (1.91% and 1.76%, respectively). Notably, 9.3% of the total infections were due to CRFs
186 and/or URFs (Hemelaar, 2011).

187 Using the Los Alamos HIV Sequences Database, we investigated the prevalence of different
188 clades over the last ten years (www.hiv.lanl.gov) in order to obtain a more recent picture of
189 the molecular epidemiology of HIV-1 in Europe. The query resulted in a total of 30,996 HIV-
190 1 sequences across Western, Central and Eastern European countries with sampling dates
191 since 2005. Overall, the results for Western and Central Europe (N=26,758) were in
192 concordance with estimates from the SPREAD/ESAR cohort and specifically B clade was
193 found to be the predominant (69.4%), followed by C (7.0%), A (3.5%), CRF02_AG (3.2%), F
194 (3.0%), G (2.9%), CRF06_cpx (2.8%) and CRF01_AE (1.7%). The countries with the highest
195 prevalence for non-B clades were Romania (85.4%), Ireland (68.2%), Luxembourg (67.2%),
196 Portugal (63.0%), Bulgaria (62.5%), Cyprus (61.1%), Finland (57.1%), Greece (54.0%),
197 United Kingdom (50.4%) and Sweden (49.2%) (**Figure 3**). In Eastern Europe (N=4,238),
198 there is a trend towards increasing prevalence of non-A clades. Specifically in the Russian
199 Federation the predominant clade is A followed by B (6.5%), CRF63_02A1 (8.9%),
200 CRF02_AG (4.0%) and C clade (1.4%). In the rest of the FSU countries having adequate
201 sampling, we found that subtype A (A_{FSU}) **remains the most prevalent clade and there**
202 **have been no spill over of non-A clades from Russia or other Western and/ or Central**
203 **European countries to these countries until to date.** The only exception was Estonia where
204 CRF06_cpx remains the predominant clade (Zetterberg et al., 2004).

205 According to the above reviewed data in Western and Central European countries, A clade
206 was the most prevalent among the non-Bs in Slovenia, Czech Republic, Poland, Greece and
207 Cyprus, C predominated in the United Kingdom and Denmark, and subtype G in Portugal.
208 Multiple clades were found at high prevalence in Switzerland (A, C, CRF01_AE,

209 CRF02_AG), Italy (C, F, G and CRF02_AG), Sweden (C and CRF01_AE), France (A, G,
210 CRF01_AE and CRF02_AG) and Spain (A, C, F, G and CRF02_AG) (**Figure 3**).

211 The approaches described above have several limitations. Specifically the SPREAD/ESAR
212 cohort enrolled only newly diagnosed individuals. Similarly, Hemelaar *et al* reviewed HIV-1
213 strains sampled between 2004 and 2007. Furthermore, the most recent published data for
214 some of the countries are relatively old. **On the other hand, figures available on the Los**
215 **Alamos HIV sequences database are more recent, but the data may not reflect actual**
216 **population frequencies and should be regarded as a rough indication of the subtype**
217 **distributions. Therefore, maps drawn using the latest approach should be interpreted**
218 **cautiously keeping in mind these limitations.**

219

220 **5. Origin of non-predominant HIV-1 clades in European countries**

221

222 Western Europe

223 **HIV-1 subtype B has been responsible for what is often called the ‘Western epidemic’ in**
224 **Europe and has remained the predominant clade despite the introduction of non-B**
225 **clades from later migrating populations. However, the prevalence of non-B subtypes has**
226 **been increasing linked to migration and later dispersal through transmission networks**
227 **with patterns varying between individual countries within the region.**

228 In the United Kingdom, HIV-1 was first identified during the 1980s among MSM with all
229 identified strains belonging to B clade (Brown et al., 1997; I., 1988; Wade et al., 1998).

230 **However, the pattern in heterosexual groups is changing with a steady increase in the**
231 **number of non-B clades since the 1990s (Hughes et al., 2009) and has mainly been**
232 **associated with sub-Saharan African and South American immigration (de Oliveira et**
233 **al., 2010; Fox et al., 2010; Resistance, 2014). Molecular epidemiological analyses revealed**
234 **that non-B sequences among heterosexuals in the UK were initially strictly linked with**
235 **strains from sub-Saharan Africa (Hughes et al., 2009), while the C clade viruses have**
236 **been associated with South America (de Oliveira et al., 2010; Resistance, 2014).**
237 **Nevertheless, a recently published study reported that the prevalence of non-B clades**
238 **among MSM increased by more than 3 times between 2002 and 2010, and, despite the**
239 **increase in non-B in heterosexual transmission networks, MSM and PWID are still at**
240 **high risk for non-B infections (Ragonnet-Cronin et al., 2016). In Ireland a similar pattern of**
241 **increasing prevalence of non-B subtypes acquired through heterosexual exposure has been**
242 **observed (De Gascun et al., 2012) and the only subtype identified in Iceland was B up until**
243 **1993 when the introduction of non-B subtypes was linked to immigration (Del Amo et al.,**

244 2011; Löve et al., 2000). **Although non-Bs were introduced into Belgium somewhat**
245 **earlier, in the mid-1980s, initial prevalence was relative low but increased over time,**
246 **from 0% in 1983 (as reported in a small two-clinical sites study) to 57% in 2001.**
247 (Fransen et al., 1996; Snoeck et al., 2004). Additionally in **Belgium and Luxembourg** 55.8%
248 of non-B infections have been detected in individuals originated from Africa, but 30.5% of
249 non-B clades were also found among native population (Dauwe et al., 2015). In **the**
250 **Netherlands the vast majority of non-Bs were linked to sub-Saharan Africa, in addition**
251 **to single cases from the Caribbean, South America, Thailand, Russia and Italy** (Bezemer
252 et al., 2004; Op de Coul et al., 1998). Immigrants from sub-Saharan Africa also introduced
253 non-B clades in **France increasing the prevalence of non-B clades from 4% in the 1980s**
254 **to more than 20% in just a decade, mostly spreading in MSM transmission networks**
255 (Barin et al., 1997; Chaix et al., 2013; Tamalet et al., 2015). Notably in a recent study, Brand
256 *et al*, found that non-B clade infections have spread among individuals of French origin and
257 especially MSM (Brand et al., 2014). Similarly Chaix *et al* found that a considerable
258 proportion of French heterosexuals (37%) with a primary infection were infected with non-B
259 clades (Chaix et al., 2013). **France is probably the only West European country where a**
260 **much higher proportion than in other countries reaching up to 23% of French Africans**
261 **citizens are infected with subtype B, suggesting that the regional sub-epidemics in native**
262 **and immigrant populations are linked** (Chaix et al., 2013; Tamalet et al., 2015).

263 Non-B clades were introduced relatively early in **Switzerland** with 28.2% of all infections as
264 non-B by the mid-1990s (Böni et al., 1999). These infections are mainly associated with
265 people of African origin (95%), heterosexual transmission (44%) and being female (43%).
266 Conversely, subtype B clade was predominant in European, American and Asian immigrants,
267 with particularly high frequencies in homosexuals (mostly MSM) (97%) and PWID (94%)
268 (Böni et al., 1999). In a study reported by von Wyl *et al*, subtype C and CRF02_AG were

269 associated with being of African origin, whilst subtype A was found at similar proportions in
270 western Europeans and Africans. However, CRF01_AE was detected more frequently among
271 Western Europeans than South East Asians. All these non-B clades were mostly associated
272 with heterosexual transmissions (von Wyl et al., 2011).

273 In **Austria**, African immigrants were identified in most cases with non-Bs suggesting Africa
274 as the putative origin of non-B infections **that subsequently spread within MSM networks**
275 (Falkensammer et al., 2007; Hoenigl et al., 2016). In **Germany**, non-B clades have been
276 detected at a 20% prevalence and were linked with migration from Sub-Saharan Africa
277 (subtype A and CRF02_AG), Eastern Europe (A_{FSU}) and South Eastern Asia (CRF01_AE)
278 **(personal communication with EIDB curators)** ((EIDB), 2016).

279 In **Finland** between 1988-1994 non-B clades were mainly transmitted heterosexually through
280 direct or indirect contact with African or Southeast Asian populations. (Liitsola, 2000). Later,
281 in 1998, Finland experienced an HIV-1 outbreak among PWID involving infections with
282 CRF01_AE, which was probably introduced from South Eastern Asia (Angelis et al., 2015;
283 Liitsola et al., 2000). In **Sweden** CRF01_AE strains circulating amongst PWID were
284 introduced from Finland (Skar et al., 2011). The rest of non-B strains including all major
285 subtypes and many different recombinants were introduced from different African regions
286 (subtype C, CRF02_AG), South Eastern Asia (CRF01_AE), but also from Eastern Europe
287 (CRF06_cpx) (Neogi et al., 2014). For **Denmark** the origin of non-B subtypes has not been
288 described in detail.

289 During the 1990s, non-B clades were also detected in **Portugal**, again linked with immigrant
290 populations mainly African. Interestingly, G clade was also reported with high prevalence
291 among PWID (34.1%, 1997-2001) (Esteves et al., 2003), unlike any other neighbouring or not
292 country in the European continent. **Although polyphyletic analyses suggested multiple and**
293 **old introductions of the B and G clades, as expected, additional non-B and non-G clades**

294 **have established local epidemics among native individuals, with the dates of the most**
295 **recent common ancestor estimated to be in the early 2000s** (Carvalho et al., 2015). As in
296 Portugal, the introduction of non-B clades in neighbouring **Spain**, was also documented in the
297 mid to late-1990s, mainly among immigrants (Soriano et al., 1997). Yebra *et al* in a study
298 from the Spanish ART Naïve cohort suggested that non-B strains were introduced by
299 immigrants and subsequently circulated among natives in Spain (Yebra et al., 2012). In a
300 study from Madrid, non-B transmissions were associated with people of African origin and
301 heterosexuals (González-Alba et al., 2011). Specifically, CRF02_AG and subtype A were
302 more frequently found among Africans, BG recombinants infected mainly PWID and BF
303 recombinants circulated only in South Americans and Spaniards (González-Alba et al., 2011).
304 **Of particular note is Galicia in Northwest Spain where PWID viruses, the G and**
305 **CRF14_BG clades were found to have originated from Portugal** (Thomson et al., 2001;
306 Thomson and Najera, 2007). Furthermore, an outbreak of subtype F1 was detected in
307 northwest Spain (mostly in Galicia) including sequences from other Western European
308 countries that were found to have originated from Southern America (Delgado et al., 2015;
309 Paraskevis et al., 2015a).

310 In **Italy**, Baldanti *et al*, showed that African ethnicity, heterosexual transmission route of
311 infection and **having a recent diagnosis (2000-2006) were independently associated with**
312 **non-B infections** (Baldanti et al., 2008). The latter was also demonstrated by Lai *et al*, who
313 studied the prevalence of HIV-1 subtypes in 3,670 individuals from 50 centres in Italy
314 between 1980 and 2008 (Lai et al., 2010). Results were very similar to the study reported by
315 Baldanti *et al*, showing that the prevalence of non-B clades increased from 2.6% in 1980-
316 1992 to 18.9% in 1993-2008, affecting mostly heterosexuals (77.2%) and people of African
317 origin (94.8% of African people carried a non-B strain) (Lai et al., 2010). **Nevertheless,**

318 **MSM transmission networks have been reported recently to drive the expansion of non-**
319 **B Italian regional sub-epidemics** (Fabeni et al., 2015; Simonetti et al., 2014).

320 In **Greece**, subtype A, the most prevalent among the non-Bs, was found to spread among the
321 native population. It was introduced from sub-Saharan Africa, **as the result of a single**
322 **founder event in the late-1970s (MRSB 1977.9; 95% highest posterior density interval,**
323 **1973.7-1981.9). The other non-A non-B clades transmissions mostly occurred amongst**
324 **heterosexual or immigrant population** (Paraskevis et al., 2007). The origin of clades
325 associated with PWID differs to the sexually transmitted epidemics in Greece. The origin of
326 the four different clades circulating among PWID during an outbreak in Athens (detected in
327 early 2011), was Afghanistan/Iran (CRF35_AD), Romania (CRF14_BG) and Greece
328 (subtypes A and B) (Niculescu et al., 2015; Paraskevis et al., 2013a; Paraskevis et al., 2015b).

329 **Whilst Israel is a West Asian country, data from here is included in the SPREAD/ESAR**
330 **cohort, and many other European studies, so is relevant for inclusions in the description**
331 **of the epidemiology of HIV-1 in Europe.** Here, non-B clades were introduced via two
332 major routes; C clade viruses originated from Ethiopia and infected mainly heterosexuals and
333 A_{FSU} clade was introduced from FSU countries and circulated and expanded mostly among
334 PWID transmission networks (Grossman et al., 2015).

335

336 Central Europe

337 **The HIV-1 epidemic in Central European countries also has the Western epidemic**
338 **pattern. Up until 1999, only B clade was detected in Polish HIV-1 infected individuals**
339 **(Stańczak et al., 2010) and mainly occurred in MSM (42%) and PWID (35%). Non-B**
340 **clades (namely A1, C, D and F1) were introduced later and detected more frequently**
341 **among heterosexuals and females** (Parczewski et al., 2012; Parczewski et al., 2010;

342 Parczewski et al., 2016). Similarly in the **Czech Republic** and **Slovakia**, non-B strains were
343 found almost exclusively in heterosexuals (Chabadova et al., 2014; Linka et al., 2008; Reinis
344 et al., 2001). Between 2008 and 2010 in **Hungary**, 96.6% of the patients were infected with
345 subtype B and 3.3% with subtype A (Mezei et al., 2011), whereas subtype C was detected
346 during the late 90s in an isolated case, where the virus was contracted in Africa (Mezei et al.,
347 2000).

348 In the **Balkan** states (Bosnia & Herzegovina, Bulgaria, Croatia, Former Yugoslav Republic of
349 Macedonia (FYROM), Montenegro and Slovenia but excluding Albania, Romania and Greece),
350 both the epidemiology and prevalence of the various HIV-1 clades are similar to Central
351 Europe and subtype B predominates in MSM (Mezei et al., 2006; Siljic et al., 2013). Other
352 subtypes, particularly recombinant subtypes, have been increasing their prevalence since the
353 beginning of the 21st century. Non-B transmissions in **Slovenia** were also associated with
354 heterosexuals in contrast to Bs, which circulated among MSM (Stanojevic et al., 2012).
355 Notably the majority of non-B infected individuals (86%) were of Slovenian nationality
356 (Lunar et al., 2013; Stanojevic et al., 2012). Interestingly, the introduction of non-B viruses in
357 **Croatia was often reported to have occurred via heterosexual contact with seamen**
358 **rather than immigrants from highly prevalent areas as is commonly found elsewhere**
359 (Ramirez-Piedad et al., 2009).

360 In **Albania**, data from the last decade showed that the local HIV-1 epidemic was
361 characterised by a high prevalence of non-B infections (65,2%) (Ciccozzi et al., 2005).
362 Specifically, A clade spread as a result of a founder effect from the A clade epidemic in
363 neighbouring Greece (Paraskevis et al., 2007; Salemi et al., 2008a). In **Bulgaria**, there are
364 several HIV-1 clades circulating and as it has been shown clades B and A1 were introduced
365 by at least three or four independent sources in last 25 years (Salemi et al., 2008b). Although
366 B clade still predominates, with higher prevalence among women and PWID, there are

367 several clades (A1, B, C, F1 and H) and CRFs (namely CRFs; 01_AE, 02_AG, 04_cpx,
368 05_DF, 14_BG, and 36_cpx) circulating among MSM and PWID, increasing the HIV-1
369 epidemic heterogeneity (Alexiev et al., 2015; Ivanov et al., 2013). In **Serbia** non-B clades
370 (i.e G, C, A, F, CRF01 and CRF02) has mainly been transmitted heterosexually (Siljic et al.,
371 2013; Stanojevic et al., 2002). In **Montenegro** there is a low prevalence of subtype A and C
372 viruses. However, the origin of the infections have not yet been identified (Ciccozzi et al.,
373 2011).

374 In **Romania**, the HIV-1 epidemic is unique as the globally-rare subtype F1 predominates and
375 any non-F1 subtypes are referred to as divergent strains. Here, significant numbers of mainly
376 institutionalised children were infected in the late 1980s via transfusion of infected blood
377 products or unsafe parenteral treatments (Apetrei et al., 1997). Estimates suggest that as many
378 as 10,000 children were infected (Lucking et al., 2013). However, B clade has been found
379 amongst MSM and heterosexuals at approximately similar rates and have in fact been found
380 to have originated from Western Europe (Paraschiv et al., 2012). There are other non-F1 and
381 non-B clades also circulating with C clade mainly being associated with heterosexuals
382 infected abroad (Paraschiv et al., 2011). Since 2010, an increasing trend of HIV-1 infections
383 amongst PWID has been observed, largely centred in Bucharest. Although F1 clade still
384 predominates in the PWID epidemic, other clades, including CRF14_BG, have also been
385 found (Niculescu et al., 2015). The outbreak of CRF4_BG strains among PWID was found to
386 have originated from Spain, whilst the two subtype F1 sub-outbreaks originated from
387 regionally prevalent Romanian strains (Paraskevis et al., 2015b).

388 **Turkey** was included in our analysis as a close, and therefore relevant, neighbour to the
389 European continent. Here, the prevalence of non-B clades was high and included many
390 different subtypes and CRFs. Unfortunately, the origin of these transmissions and/or local
391 epidemics remains unclear (Inan and Sayan, 2014; Stanojevic et al., 2002).

393 **In the Eastern European sub-continent A_{FSU} clade is the predominant and has been**
394 **spread through a large PWID-epidemic in the mid-1990s.** In the pre-PWID epidemic era,
395 an early study (mid-1980s) from Belarus, Russia and Lithuania described the presence of
396 HIV-1 subtype B clade in homosexually infected individuals and subtype C in heterosexually
397 infected individuals, while A, C, D and G clades were also detected in parentally infected
398 individuals (Lukashov et al., 1995). In the mid-1990s **Ukraine experienced the begging of a**
399 **large epidemic in the PWID communities which subsequently spread into the Russian**
400 **Federation, Belarus, Moldova, Lithuania, Latvia, Kazakhstan, Kyrgyzstan,**
401 **Turkmenistan, Georgia, Azerbaijan and Armenia** (Bobkov et al., 1998; Bobkova, 2013;
402 Saad et al., 2006b). The geographic origin of the A_{FSU} PWID-epidemic was in Odessa and the
403 tMRCA was approximately in 1993 (Diez-Fuertes et al., 2015). Moreover, the origin of the
404 A_{FSU} PWID-epidemic strain has been recently identified in Democratic Republic of Congo
405 (DRC), and the upper limit of the dispersal time for the ancestral strain in 1970 (Diez-Fuertes
406 et al., 2015). Besides the A_{FSU} that dominates in FSU countries, subtype B transmissions have
407 been described at low prevalence and are mainly associated with MSM, probably associated
408 with the Western European epidemic (Bobkova, 2013).

409 The epidemiology of the HIV-1 epidemic in the Baltic states of **Estonia, Latvia and**
410 **Lithuania** is similar to the neighbouring countries of **Belarus and Russia**, where PWID
411 transmission networks contribute significantly to the spread of the epidemic (Avi et al., 2014;
412 Lai et al., 2014). In 2000, the rapid spread of HIV-1 amongst PWID intensified; when an
413 outbreak was noted amongst PWID in Estonia's Eastern regions (Adojaan et al., 2005). This
414 was a large outbreak resulted in a prevalence to around 1000 HIV-1 infected per million,
415 consisting the highest in the European Union (Avi et al., 2014). It was recognized from the
416 early start that this outbreak involved a recombinant HIV-1 subtype which differs from the

417 predominant A clade circulating in neighbouring countries, called CRF06_cpx (Adojaan et
418 al., 2005). The Estonian CRF06_cpx strain was likely originated in Africa (Zetterberg et al.,
419 2004), and although it has been reported in other European countries, it is a minority variant
420 in all studies performed outside Estonia. Conversely, subtype A dominates in **Latvia** and
421 **Lithuania**, where the HIV-1 epidemic is otherwise very similar and driven by injecting drug
422 use (Andrews et al., 2013; Popa et al., 2013). More recently CRF02_AG has been
423 increasingly detected amongst PWID in Russia and is probably linked with the CRF02_AG
424 epidemics in Central Asia (Bobkova, 2013).

425 The origin of **non-predominant HIV-1 clades in Europe** can be described according to the
426 **following three patterns:** i) **Cross-continental transmissions:** Overall in Western Europe
427 non-B clades have mostly been associated with immigration and heterosexual intercourse.
428 This pattern has been remained consistent since the earliest stage of the epidemic. Non-B
429 transmissions were detected at different proportions amongst individuals with a non-African
430 origin in Western Europe. South Eastern Asia and **South America are also a source of non-**
431 **B clades in Western European countries, but to a lesser extent than Africa.** ii) **Cross-**
432 **border infections across Western Europe:** Non-B infections circulating across Western
433 European countries such as **subtype G infections in Luxemburg and Spain which have**
434 **originated in Portugal; CRF14_BG in Spain, which also originated in Portugal;**
435 **CRF01_AE epidemic among PWID in Sweden, which is regarded as a spill over from**
436 **Finland and the F1 clade circulating in North-West Spain and other European countries**
437 iii) **Cross-border transmissions across European areas:** In this group there are examples
438 of non-B transmissions in Eastern Europe which originated from Western Europe, such
439 as the **CRF14_BG from the Iberian Peninsula (Portugal and/or Spain) and the A_{FSU}**
440 **from Eastern Europe transmissions in Central and Western Europe introduced.** Cross-

441 border spill overs have also been discovered between Central Asia and Eastern Europe
442 (Russian Federation).

443

444 **6. HIV-1 subtypes in immigrants**

445

446 Population movements including migration from the African and Asian continents have
447 transformed European countries over the past two decades and have been linked to several
448 infectious disease outbreaks, including local HIV-1 epidemics (Kentikelenis et al., 2015).

449 In 2013, epidemiological reports showed 39.9% of new HIV-1 infections were in immigrants.

450 A large proportion of new HIV-1 infections were among immigrants from sub-Saharan Africa
451 (54.3%), Latin America (12.2%), Western Europe (9.5%), and Central Europe (6%) ((ECDC),
452 2013). Sub-Saharan Africa was identified as the origin of 13.8% of all HIV-1 diagnoses in the
453 EU/EEA, 35.0% of heterosexually acquired infections and 38.3% of mother-to-child
454 transmissions (MTCT), as shown by studies from Spain and the United Kingdom (Monge-
455 Maillo et al., 2009)

456 Based on data from numerous molecular epidemiological studies reviewed above, non-B
457 transmissions in Western Europe have been associated with immigrants from sub-Saharan
458 Africa **and to a lesser extent from South East Asia, South America and Eastern Europe.**

459 Phylogenetic analyses revealed that different proportions of regional transmissions occur
460 amongst immigrants, as for example in Switzerland, where this proportion ranged between
461 16% and 28% for several non-B clades (von Wyl et al., 2011). Lai *et al* showed that
462 individuals from the generalised epidemic were less likely to belong within local clusters than
463 individuals from South America and Italy (Lai et al., 2014). Notably, subtype B transmissions
464 were found at 23% and 3% of Africans and immigrants from sub-Saharan Africa living in
465 France and Spain, respectively, suggesting that these transmissions could have possibly
466 occurred in Europe (Chaix et al., 2013; Rivas et al., 2013).

467 Based on the fact that immigrants have mostly been infected with non-B strains, a valid
468 hypothesis is that they were infected, at least at some proportions, before migrating and

469 therefore they could provide the main source of divergent strains in Europe. This picture is
470 consistent in Western Europe where non-Bs predominate among non-Europeans. Of course
471 there are exceptions, such as Greece and Portugal, where non-B infections have been spread
472 within local sexual networks (Thomson and Najera, 2007). Notably, in Central Europe non-B
473 clades are mainly linked with heterosexual route of transmission and not with non-European
474 origin. On the other hand, non-Bs have a distinct pattern of epidemic spread in Eastern
475 European countries, for instance in FSU countries are associated with regional dispersal in
476 PWID and in Russian federation with heterosexual transmissions within local immigrants'
477 sexual networks.

478 **It is clear that migrating populations have played an important role in shaping the**
479 **genetic heterogeneity of the HIV-1 epidemic in Western Europe. This finding is**
480 **consistent with socioeconomic factors indicating higher migratory rates towards**
481 **Western European countries rather than FSU countries and Russia.**

482

483 7. Conclusions

484

485 To conclude, the complexity of the European HIV-1 epidemic has been increasing in Western
486 and Central Europe during recent years. The higher proportions of non-B clades and their
487 increasing prevalence across Western and Central Europe reflect this. Conversely, in FSU
488 countries, except Russia, the epidemic is less complex where subtype A (A_{FSU}) still
489 predominates across different areas. Our review of numerous recently published studies and
490 updated database queries suggest that the distribution of different clades greatly differs across
491 Western and Central Europe, where the most prevalent non-B clades are A, C, F and G and
492 the CRFs 01_AE and 02_AG. The introduction of divergent strains occurs mostly through
493 mobility from sub-Saharan Africa and **circulation of these strains is more frequent**
494 **amongst immigrants, local transmission networks, such as heterosexual, MSM and**
495 **PWID** (Abecasis et al., 2013). **Although the origin of HIV-1 transmissions in immigrants**
496 **warrants further investigation, preliminary analyses of the already published studies**
497 **suggests that most of those coming from Africa, mainly sub-Saharan Africa, are infected**
498 **in their country of origin (pre-migration), rather than in their hosting European country**
499 **(post-migration).**

500

501 Acknowledgments

502 AB is funded through the IKY Fellowships of Excellence for Postdoctoral Research in Greece
503 – Siemens Program. The study was partly supported by the Hellenic Society for the study of
504 AIDS and STDs. **The authors wish to thank Ms. Rachael Jones who assisted in the proof-**
505 **reading of the manuscript.**

506 **Figure Legends**

507

508 **Figure 1:** Phylogenetic tree of full-length genomic sequences from SIV infecting different
509 **monkey species (A) and HIV-1/SIVcpz (B)** shown in different colours. HIV-1 and HIV-2
510 groups are shown in red and stars indicate cross-species transmission events. **Full-length**
511 **sequence alignments were downloaded from the HIV Los Alamos sequence database.**

512 Phylogenetic tree of full-length genomic sequences from SIV infecting

513

514 **Figure 2:** HIV-1 and HIV-2 classification scheme. **In addition to groups, clades and**
515 **recombinants described in this figure, there have been named several monophyletic**
516 **clades of viruses circulating in specific geographic regions (e.g. the A_{FSU} clade including**
517 **sequences within subtype A circulating in Russia and other Former Soviet Union (FSU)**
518 **countries).**

519

520 **Figure 3:** Map of the most prevalent non-B subtypes and recombinants across Europe as
521 explained in the colour legend. The prevalence of subtype B for each country is drawn on
522 grey scale. **Information about the prevalence of HIV-1 clades was based on a query from**
523 **the Los Alamos HIV sequence database for sequences sampled later than 2005 using a**
524 **single sequence per patient.**

525

526

527 **Reference list**

528 HIV sequence database, <http://www.hiv.lanl.gov/>.

529 (ECDC), E.C.f.D.P.a.C., 2013. Annual epidemiological report Reporting on 2011 surveillance data and
530 2012 epidemic intelligence data, Annual Epidemiological Report,
531 [http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-
532 4aed-4d32-b960-af70113dbb90&ID=989](http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=989) (accessed 01/06/2016).

533 (ECDC), E.C.f.D.P.a.C., 2015. European Centre for Disease Prevention and Control:
534 HIV/AIDS surveillance in Europe 2014, Annual HIV/AIDS surveillance reports,
535 [http://ecdc.europa.eu/en/publications/surveillance_reports/HIV_STI_and_blood_borne_viruses/Pag
536 es/hiv_aids_surveillance_in_Europe.aspx](http://ecdc.europa.eu/en/publications/surveillance_reports/HIV_STI_and_blood_borne_viruses/Pages/hiv_aids_surveillance_in_Europe.aspx) (accessed 01/06/2016).

537 (EIDB), E.I.D.B., 2016. EuResist Integrated Data Base (EIDB) <http://engine.euresist.org/> (accessed
538 01/06/2016).

539 Abecasis, A.B., Wensing, A.M., Paraskevis, D., Vercauteren, J., Theys, K., Van de Vijver, D.A., Albert, J.,
540 Asjö, B., Balotta, C., Beshkov, D., Camacho, R.J., Clotet, B., De Gascun, C., Griskevicius, A., Grossman,
541 Z., Hamouda, O., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, L.G., Kücherer, C., Liitsola, K., Linka,
542 M., Nielsen, C., Otelea, D., Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Schmit, J.C., Sönnernborg,
543 A., Stanekova, D., Stanojevic, M., Struck, D., Boucher, C.A., Vandamme, A.M., 2013. HIV-1 subtype
544 distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly
545 compartmentalized epidemics. *Retrovirology* 10, 7.

546 Adojaan, M., Kivisild, T., Männik, A., Krispin, T., Ustina, V., Zilmer, K., Liebert, E., Jaroslavtsev, N.,
547 Priimägi, L., Tefanova, V., Schmidt, J., Krohn, K., VILLEMS, R., Salminen, M., Ustav, M., 2005.
548 Predominance of a rare type of HIV-1 in Estonia. *J Acquir Immune Defic Syndr* 39, 598-605.

549 AIDS, R., 2015. Information note 'Spravka' on HIV infection in the Russian Federation as of 31
550 December 2014, in: The Moscow Russian Federal Scientific Methodological Center for Prevention
551 Control, o.A. (Ed.).

552 Alexiev, I., Shankar, A., Wensing, A.M., Beshkov, D., Elenkov, I., Stoycheva, M., Nikolova, D., Nikolova,
553 M., Switzer, W.M., 2015. Low HIV-1 transmitted drug resistance in Bulgaria against a background of
554 high clade diversity. *J Antimicrob Chemother* 70, 1874-1880.

555 Andrews, E., Pearson, D., Kelly, C., Stroud, L., Rivas Perez, M., 2013. Carbon footprint of patient
556 journeys through primary care: a mixed methods approach. *Br J Gen Pract* 63, e595-603.

557 Angelis, K., Albert, J., Mamais, I., Magiorkinis, G., Hatzakis, A., Hamouda, O., Struck, D., Vercauteren,
558 J., Wensing, A.M., Alexiev, I., Åsjö, B., Balotta, C., Camacho, R.J., Coughlan, S., Griskevicius, A.,
559 Grossman, Z., Horban, A., Kostrikis, L.G., Lepej, S., Liitsola, K., Linka, M., Nielsen, C., Otelea, D.,
560 Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Schmit, J.C., Sönnnerborg, A., Staneková, D.,
561 Stanojevic, M., Boucher, C.A., Kaplan, L., Vandamme, A.M., Paraskevis, D., 2015. Global Dispersal
562 Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to
563 Heterosexual Sexual Activities Centralized in Southeast Asia. *J Infect Dis* 211, 1735-1744.

564 Apetrei, C., Loussert-Ajaka, I., Collin, G., Letourneur, F., Duca, M., Saragosti, S., Simon, F., Brun-
565 Vezinet, F., 1997. HIV type 1 subtype F sequences in Romanian children and adults. *AIDS Res Hum*
566 *Retroviruses* 13, 363-365.

567 Apetrei, C., Necula, A., Holm-Hansen, C., Loussert-Ajaka, I., Pandrea, I., Cozmei, C., Streinu-Cercel, A.,
568 Pascu, F.R., Negut, E., Molnar, G., Duca, M., Pecec, M., Brun-Vézinet, F., Simon, F., 1998. HIV-1
569 diversity in Romania. *AIDS* 12, 1079-1085.

570 Avi, R., Huik, K., Pauskar, M., Ustina, V., Karki, T., Kallas, E., Jogeda, E.L., Krispin, T., Lutsar, I., 2014.
571 Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1
572 CRF06_cpx-infected patients in Estonia in 2010. *AIDS Res Hum Retroviruses* 30, 278-283.

573 Ayouba, A., Souquieres, S., Njinku, B., Martin, P.M., Muller-Trutwin, M.C., Roques, P., Barre-Sinoussi,
574 F., Mauciere, P., Simon, F., Nerrienet, E., 2000. HIV-1 group N among HIV-1-seropositive individuals in
575 Cameroon. *AIDS* 14, 2623-2625.

576 Baldanti, F., Paolucci, S., Ravasi, G., Maccabruni, A., Moriggia, A., Barbarini, G., Maserati, R., 2008.
577 Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious
578 diseases in Northern Italy. *J Med Virol* 80, 947-952.

579 Barin, F., Courouce, A.M., Pillonel, J., Buzelay, L., 1997. Increasing diversity of HIV-1M serotypes in
580 French blood donors over a 10-year period (1985-1995). *Retrovirus Study Group of the French*
581 *Society of Blood Transfusion. AIDS* 11, 1503-1508.

582 Bezemer, D., Jurriaans, S., Prins, M., van der Hoek, L., Prins, J.M., de Wolf, F., Berkhout, B., Coutinho,
583 R., Back, N.K., 2004. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. *AIDS* 18,
584 1571-1577.

585 Bobkov, A., Cheingsong-Popov, R., Selimova, L., Ladnaya, N., Kazennova, E., Kravchenko, A.,
586 Pokrovsky, V., Weber, J., 1997. HIV type 1 subtype E in Russia. *AIDS Res Hum Retroviruses* 13, 725-
587 727.

588 Bobkov, A., Kazennova, E., Selimova, L., Bobkova, M., Khanina, T., Ladnaya, N., Kravchenko, A.,
589 Pokrovsky, V., Cheingsong-Popov, R., Weber, J., 1998. A sudden epidemic of HIV type 1 among
590 injecting drug users in the former Soviet Union: identification of subtype A, subtype B, and novel
591 gagA/envB recombinants. *AIDS research and human retroviruses* 14, 669-676.

592 Bobkov, A.F., Kazennova, E.V., Selimova, L.M., Khanina, T.A., Ryabov, G.S., Bobkova, M.R., Sukhanova,
593 A.L., Kravchenko, A.V., Ladnaya, N.N., Weber, J.N., Pokrovsky, V.V., 2004. Temporal trends in the HIV-
594 1 epidemic in Russia: predominance of subtype A. *J Med Virol* 74, 191-196.

595 Bobkova, M., 2013. Current status of HIV-1 diversity and drug resistance monitoring in the former
596 USSR. *AIDS Rev* 15, 204-212.

597 Böni, J., Pyra, H., Gebhardt, M., Perrin, L., Bürgisser, P., Matter, L., Fierz, W., Erb, P., Piffaretti, J.C.,
598 Minder, E., Grob, P., Burckhardt, J.J., Zwahlen, M., Schüpbach, J., 1999. High frequency of non-B
599 subtypes in newly diagnosed HIV-1 infections in Switzerland. *J Acquir Immune Defic Syndr* 22, 174-
600 179.

601 Brand, D., Moreau, A., Cazein, F., Lot, F., Pillonel, J., Brunet, S., Thierry, D., Le Vu, S., Plantier, J.C.,
602 Semaille, C., Barin, F., 2014. Characteristics of patients recently infected with HIV-1 non-B subtypes in
603 France: a nested study within the mandatory notification system for new HIV diagnoses. *Journal of*
604 *clinical microbiology* 52, 4010-4016.

605 Brown, A.J., Lobidel, D., Wade, C.M., Rebus, S., Phillips, A.N., Brettler, R.P., France, A.J., Leen, C.S.,
606 McMenamin, J., McMillan, A., Maw, R.D., Mulcahy, F., Robertson, J.R., Sankar, K.N., Scott, G., Wyld,
607 R., Peutherer, J.F., 1997. The molecular epidemiology of human immunodeficiency virus type 1 in six
608 cities in Britain and Ireland. *Virology* 235, 166-177.

609 Brunet, J.B., Bouvet, E., Massari, V., 1984. Epidemiological aspects of acquired immune deficiency
610 syndrome in France. *Ann N Y Acad Sci* 437, 334-339.

611 Buonaguro, L., Tornesello, M.L., Buonaguro, F.M., 2007. Human immunodeficiency virus type 1
612 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. *J Virol*
613 81, 10209-10219.

614 Camacho, R., 2006. Chapter 13: The significance of subtype-related genetic variability: controversies
615 and unanswered questions, in: Geretti, A.M. (Ed.), *Antiretroviral Resistance in Clinical Practice*.
616 Mediscript, London.

617 Carvalho, A., Costa, P., Triunfante, V., Branca, F., Rodrigues, F., Santos, C.L., Correia-Neves, M.,
618 Saraiva, M., Lecour, H., Castro, A.G., Pedrosa, J., Osorio, N.S., 2015. Analysis of a local HIV-1 epidemic
619 in portugal highlights established transmission of non-B and non-G subtypes. *J Clin Microbiol* 53,
620 1506-1514.

621 Chabadova, Z., Habekova, M., Truska, P., Drobkova, T., Mojzesova, M., Stanekova, D., 2014.
622 Distribution of HIV-1 subtypes circulating in Slovakia (2009-2012). *Acta virologica* 58, 317-324.

623 Chaix, M.L., Seng, R., Frange, P., Tran, L., Avettand-Fenoel, V., Ghosn, J., Reynes, J., Yazdanpanah, Y.,
624 Raffi, F., Goujard, C., Rouzioux, C., Meyer, L., Group, A.P.C.S., 2013. Increasing HIV-1 non-B subtype
625 primary infections in patients in France and effect of HIV subtypes on virological and immunological
626 responses to combined antiretroviral therapy. *Clin Infect Dis* 56, 880-887.

627 Ciccozzi, M., Gori, C., Boros, S., Ruiz-Alvarez, M.J., Harxhi, A., Dervishi, M., Qyra, S., Schinaia, N.,
628 D'Arrigo, R., Ceccherini-Silberstein, F., Bino, S., Perno, C.F., Rezza, G., 2005. Molecular diversity of HIV
629 in Albania. *J Infect Dis* 192, 475-479.

630 Ciccozzi, M., Vujošević, D., Lo Presti, A., Mugoša, B., Vratnica, Z., Lai, A., Laušević, D., Drašković, N.,
631 Marjanovic, A., Cella, E., Santoro, M.M., Alteri, C., Fabeni, L., Ciotti, M., Zehender, G., 2011. Genetic
632 diversity of HIV type 1 in Montenegro. *AIDS Res Hum Retroviruses* 27, 921-924.

633 D'Arc, M., Ayouba, A., Esteban, A., Learn, G.H., Boue, V., Liegeois, F., Etienne, L., Tagg, N., Leendertz,
634 F.H., Boesch, C., Madinda, N.F., Robbins, M.M., Gray, M., Cournil, A., Ooms, M., Letko, M., Simon,
635 V.A., Sharp, P.M., Hahn, B.H., Delaporte, E., Mpoudi Ngole, E., Peeters, M., 2015. Origin of the HIV-1
636 group O epidemic in western lowland gorillas. *Proc Natl Acad Sci U S A* 112, E1343-1352.

637 Dauwe, K., Mortier, V., Schauvliege, M., Van Den Heuvel, A., Fransen, K., Servais, J.Y., Bercoff, D.P.,
638 Seguin-Devaux, C., Verhofstede, C., 2015. Characteristics and spread to the native population of HIV-
639 1 non-B subtypes in two European countries with high migration rate. *BMC infectious diseases* 15,
640 524.

641 De Gascun, C.F., Waters, A., Regan, C.M., O'Halloran, J., Farrell, G., Coughlan, S., Bergin, C., Powderly,
642 W.G., Hall, W.W., 2012. Human immunodeficiency virus type 1 in Ireland: phylogenetic evidence for
643 risk group-specific subepidemics. *AIDS Res Hum Retroviruses* 28, 1073-1081.

644 de Oliveira, T., Pillay, D., Gifford, R.J., Resistance, U.K.C.G.o.H.D., 2010. The HIV-1 subtype C epidemic
645 in South America is linked to the United Kingdom. *PLoS One* 5, e9311.

646 Del Amo, J., Likatavičius, G., Pérez-Cachafeiro, S., Hernando, V., González, C., Jarrín, I., Noori, T.,
647 Hamers, F.F., Bolúmar, F., 2011. The epidemiology of HIV and AIDS reports in migrants in the 27
648 European Union countries, Norway and Iceland: 1999-2006. *Eur J Public Health* 21, 620-626.

649 Delgado, E., Cuevas, M.T., Dominguez, F., Vega, Y., Cabello, M., Fernandez-Garcia, A., Perez-Losada,
650 M., Castro, M.A., Montero, V., Sanchez, M., Marino, A., Alvarez, H., Ordonez, P., Ocampo, A.,

651 Miralles, C., Perez-Castro, S., Lopez-Alvarez, M.J., Rodriguez, R., Trigo, M., Diz-Aren, J., Hinojosa, C.,
652 Bachiller, P., Hernaez-Crespo, S., Cisterna, R., Garduno, E., Perez-Alvarez, L., Thomson, M.M., 2015.
653 Phylogeny and Phylogeography of a Recent HIV-1 Subtype F Outbreak among Men Who Have Sex
654 with Men in Spain Deriving from a Cluster with a Wide Geographic Circulation in Western Europe.
655 PloS one 10, e0143325.

656 Diez-Fuertes, F., Cabello, M., Thomson, M.M., 2015. Bayesian phylogeographic analyses clarify the
657 origin of the HIV-1 subtype A variant circulating in former Soviet Union's countries. *Infection,*
658 *genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious*
659 *diseases* 33, 197-205.

660 Easterbrook, P.J., Smith, M., Mullen, J., O'Shea, S., Chrystie, I., de Ruiter, A., Tatt, I.D., Geretti, A.M.,
661 Zuckerman, M., 2010. Impact of HIV-1 viral subtype on disease progression and response to
662 antiretroviral therapy. *Journal of the International AIDS Society* 13, 4.

663 Esteves, A., Parreira, R., Piedade, J., Venenno, T., Franco, M., Germano de Sousa, J., Patrício, L., Brum,
664 P., Costa, A., Canas-Ferreira, W.F., 2003. Spreading of HIV-1 subtype G and envB/gagG recombinant
665 strains among injecting drug users in Lisbon, Portugal. *AIDS Res Hum Retroviruses* 19, 511-517.

666 Fabeni, L., Alteri, C., Orchi, N., Gori, C., Bertoli, A., Forbici, F., Montella, F., Pennica, A., De Carli, G.,
667 Giuliani, M., Continenza, F., Pinnetti, C., Nicastri, E., Ceccherini-Silberstein, F., Mastroianni, C.M.,
668 Girardi, E., Andreoni, M., Antinori, A., Santoro, M.M., Perno, C.F., 2015. Recent Transmission
669 Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly
670 Diagnosed Men in Central Italy. *PLoS One* 10, e0135325.

671 Falkensammer, B., Doerler, M., Kessler, H.H., Puchhammer-Stoeckl, E., Parson, W., Duftner, C.,
672 Dierich, M.P., Stoiber, H., 2007. Subtype and genotypic resistance analysis of HIV-1 infected patients
673 in Austria. *Wien Klin Wochenschr* 119, 181-185.

674 Faria, N.R., Rambaut, A., Suchard, M.A., Baele, G., Bedford, T., Ward, M.J., Tatem, A.J., Sousa, J.D.,
675 Arinaminpathy, N., Pepin, J., Posada, D., Peeters, M., Pybus, O.G., Lemey, P., 2014. HIV epidemiology.
676 The early spread and epidemic ignition of HIV-1 in human populations. *Science* 346, 56-61.

677 Fox, J., Castro, H., Kaye, S., McClure, M., Weber, J.N., Fidler, S., Resistance, U.K.C.G.o.H.D., 2010.
678 Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. *AIDS* 24, 2397-
679 2401.

680 Fransen, K., Buve, A., Nkengasong, J.N., Laga, M., van der Groen, G., 1996. Longstanding presence in
681 Belgians of multiple non-B HIV-1 subtypes. *Lancet* 347, 1403.

682 Frost, S.D., Pillay, D., 2015. Understanding drivers of phylogenetic clustering in molecular
683 epidemiological studies of HIV. *J Infect Dis* 211, 856-858.

684 Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, S.F., Cummins, L.B., Arthur,
685 L.O., Peeters, M., Shaw, G.M., Sharp, P.M., Hahn, B.H., 1999. Origin of HIV-1 in the chimpanzee *Pan*
686 *troglodytes troglodytes*. *Nature* 397, 436-441.

687 Geretti, A.M., Harrison, L., Green, H., Sabin, C., Hill, T., Fearnhill, E., Pillay, D., Dunn, D., Resistance,
688 U.K.C.G.o.H.D., 2009. Effect of HIV-1 subtype on virologic and immunologic response to starting
689 highly active antiretroviral therapy. *Clin Infect Dis* 48, 1296-1305.

690 Glauser, M.P., Francioli, P., 1984. Clinical and epidemiological survey of acquired immune deficiency
691 syndrome in Europe. *Eur J Clin Microbiol* 3, 55-58.

692 González-Alba, J.M., Holguín, A., Garcia, R., García-Bujalance, S., Alonso, R., Suárez, A., Delgado, R.,
693 Cardeñoso, L., González, R., García-Bermejo, I., Portero, F., de Mendoza, C., González-Candelas, F.,
694 Galán, J.C., 2011. Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis. *J Virol*
695 85, 10755-10763.

696 Grossman, Z., Avidor, B., Mor, Z., Chowers, M., Levy, I., Shahar, E., Riesenber, K., Stoeber, Z.,
697 Maayan, S., Shao, W., Lorber, M., Olstein-Pops, K., Elbirt, D., Elinav, H., Asher, I., Averbuch, D.,
698 Istomin, V., Gottesman, B.S., Kedem, E., Girshengorn, S., Kra-Oz, Z., Shemer Avni, Y., Radian Sade, S.,
699 Turner, D., Maldarelli, F., 2015. A Population-Structured HIV Epidemic in Israel: Roles of Risk and
700 Ethnicity. *PLoS one* 10, e0135061.

701 Hemelaar, J., 2012. The origin and diversity of the HIV-1 pandemic. *Trends in molecular medicine* 18,
702 182-192.

703 Hemelaar, J., 2013. Implications of HIV diversity for the HIV-1 pandemic. *The Journal of infection* 66,
704 391-400.

705 Hemelaar, J., Gouws, E., Ghys, P. D., Osmanov, S., Isolation, WHO-UNAIDS Network for HIV
706 Characterisation, 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. *AIDS* 25,
707 679-689.

708 Hoenigl, M., Chaillon, A., Kessler, H.H., Haas, B., Stelzl, E., Weninger, K., Little, S.J., Mehta, S.R., 2016.
709 Characterization of HIV Transmission in South-East Austria. *PLoS One* 11, e0151478.

710 Hughes, G.J., Fearnhill, E., Dunn, D., Lycett, S.J., Rambaut, A., Leigh Brown, A.J., Collaboration,
711 U.H.D.R., 2009. Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.
712 PLoS Pathog 5, e1000590.

713 I., U.K.q.r., 1988. Human immunodeficiency virus infection in the United Kingdom: quarterly report I.
714 The epidemic to 30 September 1987, J Infect, pp. 291-302.

715 Inan, D., Sayan, M., 2014. Molecular epidemiology of HIV-1 strains in Antalya, Turkey. Journal of the
716 International AIDS Society 17, 19684.

717 Ivanov, I.A., Beshkov, D., Shankar, A., Hanson, D.L., Paraskevis, D., Georgieva, V., Karamacheva, L.,
718 Taskov, H., Varleva, T., Elenkov, I., Stoicheva, M., Nikolova, D., Switzer, W.M., 2013. Detailed
719 molecular epidemiologic characterization of HIV-1 infection in Bulgaria reveals broad diversity and
720 evolving phylodynamics. PLoS One 8, e59666.

721 Kentikelenis, A., Karanikolos, M., Williams, G., Mladovsky, P., King, L., Pharris, A., Suk, J.E., Hatzakis,
722 A., McKee, M., Noori, T., Stuckler, D., 2015. How do economic crises affect migrants' risk of infectious
723 disease? A systematic-narrative review. Eur J Public Health 25, 937-944.

724 Kuhnert, D., Stadler, T., Vaughan, T.G., Drummond, A.J., 2014. Simultaneous reconstruction of
725 evolutionary history and epidemiological dynamics from viral sequences with the birth-death SIR
726 model. J R Soc Interface 11, 20131106.

727 Laga, V., Vasilyev, A., Lapovok, I., Grigoryan, S., Papoyan, A., Glushchenko, N., Kazennova, E.,
728 Bobkova, M., 2015. HIV Type 1 Subtype A1 Dominates in Armenia. Curr HIV Res 13, 219-225.

729 Lai, A., Bozzi, G., Franzetti, M., Binda, F., Simonetti, F.R., Micheli, V., Meraviglia, P., Corsi, P.,
730 Bagnarelli, P., De Luca, A., Ciccozzi, M., Zehender, G., Zazzi, M., Balotta, C., 2014. Phylogenetic
731 analysis provides evidence of interactions between Italian heterosexual and South American
732 homosexual males as the main source of national HIV-1 subtype C epidemics. *Journal of medical*
733 *virology* 86, 729-736.

734 Lai, A., Riva, C., Marconi, A., Balestrieri, M., Razzolini, F., Meini, G., Vicenti, I., Rosi, A., Saladini, F.,
735 Caramma, I., Franzetti, M., Rossini, V., Galli, A., Galli, M., Violin, M., Zazzi, M., Balotta, C., 2010.
736 Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. *HIV Med*
737 11, 593-602.

738 Liitsola, K., Holmström, P., Laukkanen, T., Brummer-Korvenkontio, H., Leinikki, P., Salminen, M.O.,
739 2000. Analysis of HIV-1 genetic subtypes in Finland reveals good correlation between molecular and
740 epidemiological data. *Scand J Infect Dis* 32, 475-480.

741 Liitsola, K., Ristola, M., Holmström, P., Salminen, M., Brummer-Korvenkontio, H., Simola, S., Suni, J.,
742 Leinikki, P., 2000. An outbreak of the circulating recombinant form AECM240 HIV-1 in the Finnish
743 injection drug user population. *AIDS* 14, 2613-2615.

744 Linka, M., Brůčková, M., Malý, M., Vandasová, J., Stanková, M., Reinis, M., 2008. A study of HIV-1
745 genetic diversity in the Czech Republic: 1986-2007. *Cent Eur J Public Health* 16, 175-177.

746 Löve, A., Chen, M., Sällberg, M., 2000. Changing profile of HIV-1 serotypes in Iceland during 1989-96.
747 *Scand J Infect Dis* 32, 445-446.

748 Lucking, R., Tehler, A., Bungartz, F., Rivas Plata, E., Lumbsch, H.T., 2013. Journey from the West: did
749 tropical Graphidaceae (lichenized Ascomycota: Ostropales) evolve from a saxicolous ancestor along
750 the American Pacific coast? *Am J Bot* 100, 844-856.

751 Lukashov, V.V., Cornelissen, M.T., Goudsmit, J., Papuashvili, M.N., Rytik, P.G., Khaitov, R.M.,
752 Karamov, E.V., de Wolf, F., 1995. Simultaneous introduction of distinct HIV-1 subtypes into different
753 risk groups in Russia, Byelorussia and Lithuania. *AIDS* 9, 435-439.

754 Lunar, M.M., Zidovec Lepej, S., Abecasis, A.B., Tomazic, J., Vidmar, L., Karner, P., Vovko, T.D., Pecavar,
755 B., Maver, P.J., Seme, K., Poljak, M., 2013. Short communication: prevalence of HIV type 1
756 transmitted drug resistance in Slovenia: 2005-2010. *AIDS Res Hum Retroviruses* 29, 343-349.

757 Melbye, M., Biggar, R.J., Ebbesen, P., Sarngadharan, M.G., Weiss, S.H., Gallo, R.C., Blattner, W.A.,
758 1984. Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission,
759 and disease outcome. *Br Med J (Clin Res Ed)* 289, 573-575.

760 Mezei, M., Ay, E., Koroknai, A., Tóth, R., Balázs, A., Bakos, A., Gyori, Z., Bánáti, F., Marschalkó, M.,
761 Kárpáti, S., Minárovits, J., 2011. Molecular epidemiological analysis of env and pol sequences in
762 newly diagnosed HIV type 1-infected, untreated patients in Hungary. *AIDS Res Hum Retroviruses* 27,
763 1243-1247.

764 Mezei, M., Balog, K., Babic, D.Z., Toth, G., Cech, G., Vajna, B., Tauber, T., Seme, K., Tomazic, J.,
765 Vidmar, L., Poljak, M., Minarovits, J., 2006. Genetic variability of gag and env regions of HIV type 1
766 strains circulating in Slovenia. *AIDS Res Hum Retroviruses* 22, 109-113.

767 Mezei, M., Balog, K., Takács, M., Tóth, G., Gyuris, A., Segesdi, J., Bakos, A., Vödrös, D., Bánhegyi, D.,
768 Berencsi, G., Minárovits, J., 2000. Genetic subtypes of HIV type 1 in Hungary. *AIDS Res Hum*
769 *Retroviruses* 16, 513-516.

770 Monge-Maillo, B., Jimenez, B.C., Perez-Molina, J.A., Norman, F., Navarro, M., Perez-Ayala, A.,
771 Herrero, J.M., Zamarron, P., Lopez-Velez, R., 2009. Imported infectious diseases in mobile
772 populations, Spain. *Emerging infectious diseases* 15, 1745-1752.

773 Neogi, U., Haggblom, A., Santacatterina, M., Bratt, G., Gisslen, M., Albert, J., Sonnerborg, A., 2014.
774 Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms
775 over three decades. *PloS one* 9, e99390.

776 Niculescu, I., Paraschiv, S., Paraskevis, D., Abagiu, A., Batan, I., Banica, L., Otelea, D., 2015. Recent
777 HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG
778 and Subtype F1 Strains. *AIDS research and human retroviruses* 31, 488-495.

779 Novitsky, V.A., Montano, M.A., Essex, M., 1998. Molecular epidemiology of an HIV-1 subtype A
780 subcluster among injection drug users in the Southern Ukraine. *AIDS Res Hum Retroviruses* 14, 1079-
781 1085.

782 Op de Coul, E.L., Lukashov, V.V., van Doornum, G.J., Goudsmit, J., Coutinho, R.A., 1998. Multiple HIV-
783 1 subtypes present amongst heterosexuals in Amsterdam 1988-1996: no evidence for spread of non-
784 B subtypes. *AIDS* 12, 1253-1255.

785 Paraschiv, S., Foley, B., Otelea, D., 2011. Diversity of HIV-1 subtype C strains isolated in Romania.
786 *Infect Genet Evol* 11, 270-275.

787 Paraschiv, S., Otelea, D., Batan, I., Baicus, C., Magiorkinis, G., Paraskevis, D., 2012. Molecular typing
788 of the recently expanding subtype B HIV-1 epidemic in Romania: evidence for local spread among
789 MSMs in Bucharest area. *Infection, genetics and evolution : journal of molecular epidemiology and*
790 *evolutionary genetics in infectious diseases* 12, 1052-1057.

791 Paraschiv, S., Otelea, D., Dinu, M., Maxim, D., Tinischi, M., 2007. Polymorphisms and resistance
792 mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. *Int J*
793 *Infect Dis* 11, 123-128.

794 Paraskevis, D., Kostaki, E., Beloukas, A., Canizares, A., Aguilera, A., Rodriguez, J., Grandal, M., Pernas,
795 B., Castro-Iglesias, A., Mena, A., Pedreira, J.D., Poveda, E., 2015a. Molecular characterization of HIV-1
796 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak. *Infect Genet Evol*
797 30, 96-101.

798 Paraskevis, D., Magiorkinis, E., Magiorkinis, G., Sypsa, V., Pappas, V., Lazanas, M., Gargalianos, P.,
799 Antoniadou, A., Panos, G., Chrysos, G., Sambatakou, H., Karafoulidou, A., Skoutelis, A., Kordossis, T.,
800 Koratzanis, G., Theodoridou, M., Daikos, G.L., Nikolopoulos, G., Pybus, O.G., Hatzakis, A.,
801 Heterogeneity, M.S.o.H., 2007. Increasing prevalence of HIV-1 subtype A in Greece: estimating
802 epidemic history and origin. *J Infect Dis* 196, 1167-1176.

803 Paraskevis, D., Nikolopoulos, G., Fotiou, A., Tsiara, C., Paraskeva, D., Sypsa, V., Lazanas, M.,
804 Gargalianos, P., Psychogiou, M., Skoutelis, A., Wiessing, L., Friedman, S.R., Jarlais, D.C., Terzidou, M.,
805 Kremastinou, J., Malliori, M., Hatzakis, A., 2013a. Economic recession and emergence of an HIV-1
806 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. *PLoS one* 8, e78941.

807 Paraskevis, D., Paraschiv, S., Sypsa, V., Nikolopoulos, G., Tsiara, C., Magiorkinis, G., Psychogiou, M.,
808 Flampouris, A., Mardarescu, M., Niculescu, I., Batan, I., Malliori, M., Otelea, D., Hatzakis, A., 2015b.

809 Enhanced HIV-1 surveillance using molecular epidemiology to study and monitor HIV-1 outbreaks
810 among intravenous drug users (IDUs) in Athens and Bucharest. *Infection, genetics and evolution :
811 journal of molecular epidemiology and evolutionary genetics in infectious diseases* 35, 109-121.

812 Paraskevis, D., Touloumi, G., Bakoyannis, G., Papanicolaou, V., Lazanas, M., Gargalianos, P., Chryssos, G.,
813 Antoniadou, A., Psychogiou, M., Panos, G., Katsarou, O., Sambatakou, H., Kordossis, T., Hatzakis, A.,
814 Amacs, 2013b. Effect of HIV type 1 subtype on virological and immunological response to
815 combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than
816 subtype B-infected Greek individuals. *AIDS Res Hum Retroviruses* 29, 461-469.

817 Parczewski, M., Leszczyszyn-Pynka, M., Bander, D., Urbanska, A., Boron-Kaczmarska, A., 2012. HIV-1
818 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical
819 analysis. *PLoS One* 7, e31674.

820 Parczewski, M., Leszczyszyn-Pynka, M., Bander, D., Urbańska, A., Stańczak, G., Boroń-Kaczmarska, A.,
821 2010. Characteristics of HIV-1 non-B subtype infections in Northwest Poland. *J Med Virol* 82, 1306-
822 1313.

823 Parczewski, M., Leszczyszyn-Pynka, M., Witak-Jedra, M., Rymer, W., Zalewska, M., Gasiorowski, J.,
824 Bociaga-Jasik, M., Kalinowska-Nowak, A., Garlicki, A., Grzeszczuk, A., Jankowska, M., Lemanska, M.,
825 Baralkiewicz, G., Mozer-Lisewska, I., Lojewski, W., Grabczewska, E., Olczak, A., Jablonowska, E.,
826 Urbanska, A., 2016. Distribution and time trends of HIV-1 variants in Poland: Characteristics of non-B
827 clades and recombinant viruses. *Infection, genetics and evolution : journal of molecular
828 epidemiology and evolutionary genetics in infectious diseases* 39, 232-240.

829 Peeters, M., Gueye, A., Mboup, S., Bibollet-Ruche, F., Ekaza, E., Mulanga, C., Ouedrago, R., Gandji, R.,
830 Mpele, P., Dibanga, G., Koumare, B., Saidou, M., Esu-Williams, E., Lombart, J.P., Badombena, W., Luo,

831 N., Vanden Haesevelde, M., Delaporte, E., 1997. Geographical distribution of HIV-1 group O viruses in
832 Africa. *AIDS* 11, 493-498.

833 Peeters, M., Honore, C., Huet, T., Bedjabaga, L., Ossari, S., Bussi, P., Cooper, R.W., Delaporte, E.,
834 1989. Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees
835 in Gabon. *AIDS* 3, 625-630.

836 Peeters, M., Sharp, P.M., 2000. Genetic diversity of HIV-1: the moving target. *AIDS* 14 Suppl 3, S129-
837 140.

838 Plantier, J.C., Leoz, M., Dickerson, J.E., De Oliveira, F., Cordonnier, F., Leme, V., Damond, F.,
839 Robertson, D.L., Simon, F., 2009. A new human immunodeficiency virus derived from gorillas. *Nat*
840 *Med* 15, 871-872.

841 Popa, I., Berkovich, R., Alegre-Cebollada, J., Badilla, C.L., Rivas-Pardo, J.A., Taniguchi, Y., Kawakami,
842 M., Fernandez, J.M., 2013. Nanomechanics of HaloTag tethers. *J Am Chem Soc* 135, 12762-12771.

843 Pybus, O.G., Rambaut, A., 2009. Evolutionary analysis of the dynamics of viral infectious disease. *Nat*
844 *Rev Genet* 10, 540-550.

845 Ragonnet-Cronin, M., Lycett, S.J., Hodcroft, E.B., Hue, S., Fearnhill, E., Brown, A.E., Delpech, V., Dunn,
846 D., Leigh Brown, A.J., United Kingdom, H.I.V.D.R.D., 2016. Transmission of Non-B HIV Subtypes in the
847 United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. *J Infect Dis*
848 213, 1410-1418.

849 Ramirez-Piedad, M.K., Lepej, S.Z., Yerly, S., Begovac, J., 2009. High prevalence of non-B HIV-1
850 subtypes in seamen and their sexual partners in Croatia. *J Med Virol* 81, 573-577.

851 Reinis, M., Brucková, M., Graham, R.R., Vandasová, J., Stanková, M., Carr, J.K., 2001. Genetic
852 subtypes of HIV type 1 viruses circulating in the Czech Republic. *AIDS Res Hum Retroviruses* 17, 1305-
853 1310.

854 Resistance, U.K.C.G.o.H.D., 2014. The increasing genetic diversity of HIV-1 in the UK, 2002-2010. *AIDS*
855 28, 773-780.

856 Rivas, P., Herrero, M.D., Poveda, E., Madejon, A., Trevino, A., Gutierrez, M., Ladron de Guevara, C.,
857 Lago, M., de Mendoza, C., Soriano, V., Puente, S., 2013. Hepatitis B, C, and D and HIV infections
858 among immigrants from Equatorial Guinea living in Spain. *Am J Trop Med Hyg* 88, 789-794.

859 Robbins, K.E., Lemey, P., Pybus, O.G., Jaffe, H.W., Youngpairoj, A.S., Brown, T.M., Salemi, M.,
860 Vandamme, A.M., Kalish, M.L., 2003. U.S. Human immunodeficiency virus type 1 epidemic: date of
861 origin, population history, and characterization of early strains. *J Virol* 77, 6359-6366.

862 Saad, M.D., Aliev, Q., Botros, B.A., Carr, J.K., Gomatos, P.J., Nadai, Y., Michael, A.A., Nasibov, Z.,
863 Sanchez, J.L., Brix, D.I., Earhart, K.C., 2006a. Genetic forms of HIV Type 1 in the former Soviet Union
864 dominate the epidemic in Azerbaijan. *AIDS Res Hum Retroviruses* 22, 796-800.

865 Saad, M.D., Shcherbinskaya, A.M., Nadai, Y., Kruglov, Y.V., Antonenko, S.V., Lyullchuk, M.G.,
866 Kravchenko, O.N., Earhart, K.C., Sanchez, J.L., Brix, D.L., Carr, J.K., 2006b. Molecular epidemiology of
867 HIV Type 1 in Ukraine: birthplace of an epidemic. *AIDS research and human retroviruses* 22, 709-714.

868 Salemi, M., de Oliveira, T., Ciccozzi, M., Rezza, G., Goodenow, M.M., 2008a. High-resolution
869 molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania. *PLoS One* 3, e1390.

870 Salemi, M., Goodenow, M.M., Montieri, S., de Oliveira, T., Santoro, M.M., Beshkov, D., Alexiev, I.,
871 Elenkov, I., Yakimova, T., Varleva, T., Rezza, G., Ciccozzi, M., 2008b. The HIV type 1 epidemic in
872 Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East
873 European countries. *AIDS Res Hum Retroviruses* 24, 771-779.

874 Santoro, M.M., Perno, C.F., 2013. HIV-1 Genetic Variability and Clinical Implications. *ISRN Microbiol*
875 2013, 481314.

876 Scherrer, A.U., Ledergerber, B., von Wyl, V., Boni, J., Yerly, S., Klimkait, T., Burgisser, P., Rauch, A.,
877 Hirschel, B., Cavassini, M., Elzi, L., Vernazza, P.L., Bernasconi, E., Held, L., Gunthard, H.F., Swiss,
878 H.I.V.C.S., 2011. Improved virological outcome in White patients infected with HIV-1 non-B subtypes
879 compared to subtype B. *Clin Infect Dis* 53, 1143-1152.

880 Seillier-Moiseiwitsch, F., Margolin, B.H., Swanstrom, R., 1994. Genetic variability of the human
881 immunodeficiency virus: statistical and biological issues. *Annu Rev Genet* 28, 559-596.

882 Siemieniuk, R.A., Beckthold, B., Gill, M.J., 2013. Increasing HIV subtype diversity and its clinical
883 implications in a sentinel North American population. *Can J Infect Dis Med Microbiol* 24, 69-73.

884 Siljic, M., Salemovic, D., Jevtovic, D., Pesic-Pavlovic, I., Zerjav, S., Nikolic, V., Ranin, J., Stanojevic, M.,
885 2013. Molecular typing of the local HIV-1 epidemic in Serbia. *Infect Genet Evol* 19, 378-385.

886 Simon, F., Mauclore, P., Roques, P., Loussert-Ajaka, I., Muller-Trutwin, M.C., Saragosti, S., Georges-
887 Courbot, M.C., Barre-Sinoussi, F., Brun-Vezinet, F., 1998. Identification of a new human
888 immunodeficiency virus type 1 distinct from group M and group O. *Nat Med* 4, 1032-1037.

889 Simonetti, F.R., Lai, A., Monno, L., Binda, F., Brindicci, G., Punzi, G., Bozzi, G., Violin, M., Galli, M.,
890 Zazzi, M., Angarano, G., Balotta, C., 2014. Identification of a new HIV-1 BC circulating recombinant
891 form (CRF60_BC) in Italian young men having sex with men. *Infect Genet Evol* 23, 176-181.

892 Skar, H., Axelsson, M., Berggren, I., Thalme, A., Gyllensten, K., Liitsola, K., Brummer-Korvenkontio, H.,
893 Kivelä, P., Spångberg, E., Leitner, T., Albert, J., 2011. Dynamics of two separate but linked HIV-1
894 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. *J Virol*
895 85, 510-518.

896 Snoeck, J., Van Laethem, K., Hermans, P., Van Wijngaerden, E., Derdelinckx, I., Schrooten, Y., van de
897 Vijver, D.A., De Wit, S., Clumeck, N., Vandamme, A.M., 2004. Rising prevalence of HIV-1 non-B
898 subtypes in Belgium: 1983-2001. *J Acquir Immune Defic Syndr* 35, 279-285.

899 Soriano, V., Dietrich, U., Mas, A., Andersen, R., Bravo, R., Ruppach, H., Gutiérrez, M., Martínez-
900 Zapico, R., Rübsamen-Waigmann, H., González-Lahoz, J., 1997. [Serotypes of the human
901 immunodeficiency virus type 1 in Madrid]. *Med Clin (Barc)* 108, 217-220.

902 Stadler, T., Bonhoeffer, S., 2013. Uncovering epidemiological dynamics in heterogeneous host
903 populations using phylogenetic methods. *Philos Trans R Soc Lond B Biol Sci* 368, 20120198.

904 Stadler, T., Kouyos, R., von Wyl, V., Yerly, S., Boni, J., Burgisser, P., Klimkait, T., Joos, B., Rieder, P., Xie,
905 D., Gunthard, H.F., Drummond, A.J., Bonhoeffer, S., 2012. Estimating the basic reproductive number
906 from viral sequence data. *Mol Biol Evol* 29, 347-357.

907 Stańczak, G.P., Stańczak, J.J., Marczyńska, M., Firlag-Burkacka, E., Wiercińska-Drapało, A.,
908 Leszczyszyn-Pynka, M., Jabłonowska, E., Małolepsza, E., Dyda, T., Zabek, P., Horban, A., 2010.

909 Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008. *J Med Virol*
910 82, 1291-1294.

911 Stanojevic, M., Alexiev, I., Beshkov, D., Gökengin, D., Mezei, M., Minarovits, J., Otelea, D., Paraschiv,
912 S., Poljak, M., Zidovec-Lepej, S., Paraskevis, D., 2012. HIV-1 molecular epidemiology in the Balkans: a
913 melting pot for high genetic diversity. *AIDS Rev* 14, 28-36.

914 Stanojevic, M., Papa, A., Papadimitriou, E., Zerjav, S., Jevtovic, D., Salemovic, D., Jovanovic, T.,
915 Antoniadis, A., 2002. HIV-1 subtypes in Yugoslavia. *AIDS Res Hum Retroviruses* 18, 519-522.

916 Tamalet, C., Ravaux, I., Moreau, J., Bregigeon, S., Tourres, C., Richet, H., Abat, C., Colson, P., 2015.
917 Emergence of clusters of CRF02_AG and B human immunodeficiency viral strains among men having
918 sex with men exhibiting HIV primary infection in southeastern France. *J Med Virol* 87, 1327-1333.

919 Tebit, D.M., Arts, E.J., 2011. Tracking a century of global expansion and evolution of HIV to drive
920 understanding and to combat disease. *Lancet Infect Dis* 11, 45-56.

921 Thomson, M.M., Delgado, E., Manjon, N., Ocampo, A., Villahermosa, M.L., Marino, A., Herrero, I.,
922 Cuevas, M.T., Vazquez-de Parga, E., Perez-Alvarez, L., Medrano, L., Taboada, J.A., Najera, R., Spanish
923 Group for Antiretroviral Studies in, G., 2001. HIV-1 genetic diversity in Galicia Spain: BG intersubtype
924 recombinant viruses circulating among injecting drug users. *AIDS* 15, 509-516.

925 Thomson, M.M., Najera, R., 2007. Increasing HIV-1 genetic diversity in Europe. *J Infect Dis* 196, 1120-
926 1124.

927 Thomson, M.M., Vinogradova, A., Delgado, E., Rakhmanova, A., Yakovlev, A., Cuevas, M.T., Muñoz,
928 M., Pinilla, M., Vega, Y., Pérez-Alvarez, L., Osmanov, S., Nájera, R., 2009. Molecular epidemiology of

929 HIV-1 in St Petersburg, Russia: predominance of subtype A, former Soviet Union variant, and
930 identification of intrasubtype subclusters. *J Acquir Immune Defic Syndr* 51, 332-339.

931 Touloumi, G., Pantazis, N., Pillay, D., Paraskevis, D., Chaix, M.L., Bucher, H.C., Kücherer, C., Zangerle,
932 R., Kran, A.M., Porter, K., EuroCoord, C.c.i., 2013. Impact of HIV-1 subtype on CD4 count at HIV
933 seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. *Clin*
934 *Infect Dis* 56, 888-897.

935 UNAIDS, 2013. Global report: UNAIDS Report on the global AIDS epidemic 2013.

936 Vallari, A., Holzmayer, V., Harris, B., Yamaguchi, J., Ngansop, C., Makamche, F., Mbanya, D., Kaptue,
937 L., Ndembi, N., Gurtler, L., Devare, S., Brennan, C.A., 2011. Confirmation of putative HIV-1 group P in
938 Cameroon. *J Virol* 85, 1403-1407.

939 Van Heuverswyn, F., Li, Y., Neel, C., Bailes, E., Keele, B.F., Liu, W., Loul, S., Butel, C., Liegeois, F.,
940 Bienvenue, Y., Ngolle, E.M., Sharp, P.M., Shaw, G.M., Delaporte, E., Hahn, B.H., Peeters, M., 2006.
941 Human immunodeficiency viruses: SIV infection in wild gorillas. *Nature* 444, 164.

942 von Wyl, V., Kouyos, R.D., Yerly, S., Böni, J., Shah, C., Bürgisser, P., Klimkait, T., Weber, R., Hirschel, B.,
943 Cavassini, M., Staehelin, C., Battegay, M., Vernazza, P.L., Bernasconi, E., Ledergerber, B., Bonhoeffer,
944 S., Günthard, H.F., Study, S.H.C., 2011. The role of migration and domestic transmission in the spread
945 of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 204, 1095-1103.

946 Wade, C.M., Lobidel, D., Brown, A.J., 1998. Analysis of human immunodeficiency virus type 1 env and
947 gag sequence variants derived from a mother and two vertically infected children provides evidence
948 for the transmission of multiple sequence variants. *J Gen Virol* 79 (Pt 5), 1055-1068.

949 Yebra, G., de Mulder, M., Martin, L., Rodriguez, C., Labarga, P., Viciano, I., Berenguer, J., Aleman,
950 M.R., Pineda, J.A., Garcia, F., Holguin, A., 2012. Most HIV type 1 non-B infections in the Spanish
951 cohort of antiretroviral treatment-naive HIV-infected patients (CoRIS) are due to recombinant
952 viruses. *Journal of clinical microbiology* 50, 407-413.

953 Zarandia, M., Tsertsvadze, T., Carr, J.K., Nadai, Y., Sanchez, J.L., Nelson, A.K., 2006. HIV-1 genetic
954 diversity and genotypic drug susceptibility in the Republic of Georgia. *AIDS Res Hum Retroviruses* 22,
955 470-476.

956 Zetterberg, V., Ustina, V., Liitsola, K., Zilmer, K., Kalikova, N., Sevastianova, K., Brummer-
957 Korvenkontio, H., Leinikki, P., Salminen, M.O., 2004. Two viral strains and a possible novel
958 recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in
959 Estonia. *AIDS Res Hum Retroviruses* 20, 1148-1156.

960

Figure 1a
[Click here to download high resolution image](#)




Figure 1b
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)

